Roche plans to present data at a major multiple sclerosis (MS) conference indicating the continued efficacy of its investigational Bruton kinase (BTK) inhibitor fenebrutinib, along with data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback